[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nordlandssykehuset HF\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100537116","clinical-research-on-acute-intermittent-porphyria-and-the-use-of-carbohydrate-rich-diet-as-a-treatment-100537116",false,"NCT06273644","Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment","Inclusion Criteria:\n\n* Diagnosis of AIP\n\nExclusion Criteria:\n\n* Not having diagnosis of AIP\n* Undergoing treatment as part of other clinical research on AIP\n* Pregnancy\n* Diabetes\n* Below 18 years of age","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","The main aim of this clinical trial is to learn about the effect of carbohydrate-rich diet as a treatment for AIP (acute intermittent porphyria).\n\nAim: Investigate the diet's impact on tissue and serum glucose, plasma insulin, cytokine levels, amino acids, and gut microbiota in AIP, and their correlation with PBG (Porphobilinogen).\n\nAim: Assess the diet's effect on AIP symptoms and health status in AIP. Aim: Measure the effect of a high-carbohydrate diet on mitochondrial activity in AIP Aim: Map and detect potential mutations in mitochondrial genomic DNA in AIP Aim: Discover new markers in AIP through RNA sequencing and machine learning.\n\nParticipants will follow two diet plans, a 4-week intervention with 60-65 E% carbohydrates and a 4 week intervention with 40-45 E% carbohydrates.",[25],"Porphyria, Acute Intermittent","RECRUITING","2026-03-25",{"date":29,"type":30},"2026-03-27","ACTUAL",{"date":32,"type":30},"2024-01-27",{"date":34,"type":19},"2037-12-31",{"name":36,"class":37},"Nordlandssykehuset HF","OTHER",3,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100552674","safer-personalised-cancer-treatment-digital-follow-up-100552674","NCT06476158","Safer Personalised Cancer Treatment Digital Follow-up","Monitoring of Adverse Events Caused by Systemic Cancer Treatment. Identifying Adverse Events Related to Immunotherapy Treatment Before and After Implementation of Personalized Digital Patient Reported Outcomes","SPecT","Inclusion Criteria:\n\n* Above 18 years of age\n* Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification\n* Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications.\n\nExclusion Criteria:\n\n* Hematological cancer\n* Gynecological cancer",{"count":48,"type":19},900,[22],"The goal of this clinical trial is to investigate patient harm\u002F adverse events, overall survival and health related quality of life under treatment with immunotherapy medication in cancer patients when they are followed up by a personalized digital program where the patients report symptoms directly to health care personnel.\n\nThe main questions the clinical trial aims to answer are:\n\n* How often and how severe are immunotherapy related adverse events\u002F side effects when patients are followed up by a digital personalized patient-reporting system compared to standard follow-up?\n* How are life quality and survival affected for patients followed up by a digital personalized patient-reporting system compared to follow-up standard follow-up??\n\nParticipants under immunotherapy cancer treatment will be followed up by a digital patient reporting program in one group, and compared to a group of cancer patients receiving the same treatment, but with standard follow-up without a digital program in another group. Researchers will compare the two groups to see if there any differences in how many patients who develop immunotherapy related patient harm and how long the patients live.",[52],"Patient Reported Outcome Measure",[54,55,56,57,58],"Adverse events","Patient reported outcome","Digital follow-up","Immunotherapy","Routine cancer care","2024-06-20",{"date":61,"type":30},"2024-06-26",{"date":63,"type":30},"2024-06-01",{"date":65,"type":19},"2027-12-31",{"name":36,"class":37},1,""]